Human prion diseases: from kuru to variant creutzfeldt-jakob disease, Subcell Biochem, vol.65, pp.457-496, 2012. ,
Molecular pathology, classification, and diagnosis of sporadic human prion disease variants, Folia Neuropathol, vol.50, pp.20-45, 2012. ,
Novel proteinaceous infectious particles cause scrapie, Science, vol.216, pp.136-144, 1982. ,
Mice devoid of PrP are resistant to scrapie, Cell, vol.73, pp.1339-1347, 1993. ,
No propagation of prions in mice devoid of PrP, Cell, vol.77, pp.967-968, 1994. ,
Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis, Science, vol.302, pp.871-874, 2003. ,
Lessons from Nature: microRNAbased shRNA libraries, Nat Methods, vol.3, pp.707-714, 2006. ,
RNA interference, Nature, vol.418, pp.244-251, 2002. ,
Rational targeting for prion therapeutics, Nat Rev Neurosci, vol.6, pp.23-34, 2005. ,
Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice, Neuron, vol.53, pp.325-335, 2007. ,
Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease, Proc Natl Acad Sci U S A, vol.105, pp.10238-10243, 2008. ,
RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?, CNS Neurol Disord Drug Targets, vol.8, pp.342-352, 2009. ,
Therapy for prion diseases: Insights from the use of RNA interference, Prion, vol.3, pp.121-128, 2009. ,
NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease, Neurobiol Dis, vol.48, pp.282-289, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01545519
Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system, Eur J Clin Invest, vol.36, pp.98-104, 2006. ,
The origin and metabolism of a nascent pre-beta high density lipoprotein involved in cellular cholesterol efflux, Acta Biochim Pol, vol.58, pp.275-285, 2011. ,
Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL, J Mol Med (Berl), vol.84, pp.276-294, 2006. ,
An historical perspective on efforts to treat transmissible spongiform encephalopathy, CNS Neurol Disord Drug Targets, vol.8, pp.316-322, 2009. ,
Effective gene therapy in a mouse model of prion diseases, PLoS ONE, vol.3, p.2773, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-01667611
Gene and cell therapy for prion diseases, Infect Disord Drug Targets, vol.9, pp.58-68, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00367789
Stem cell therapy extends incubation and survival time in prion-infected mice in a time window-dependant manner, J Infect Dis, pp.1038-1045, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00635996
Liposome-siRNApeptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures, PLoS ONE, vol.5, p.11085, 2010. ,